About CalciMedica
CalciMedica is a company based in San Diego (United States) founded in 2006 by Kenneth Stauderman. CalciMedica has raised $76.66 million across 16 funding rounds from investors including Biogen, HHS and Avenue Capital Group. The company has 14 employees as of December 31, 2024. CalciMedica offers products and services including Auxora and CRAC Channel Inhibitors. CalciMedica operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 14 as on 31 Dec, 2024
- Founders Kenneth Stauderman
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Calcimedica, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$13.7 M (USD)60.12as on Dec 31, 2024
-
EBITDA
-$24.15 M (USD)-10.68as on Dec 31, 2024
-
Total Equity Funding
$76.66 M (USD)
in 16 rounds
-
Latest Funding Round
$32.5 M (USD), Debt – Conventional
Apr 06, 2025
-
Investors
Biogen
& 7 more
-
Employee Count
14
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CalciMedica
CalciMedica is a publicly listed company on the NASDAQ with ticker symbol CALC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CalciMedica
CalciMedica offers a comprehensive portfolio of products and services, including Auxora and CRAC Channel Inhibitors.
CRAC channel inhibitor targeting inflammatory diseases in pancreas and kidney
Modulates immune responses for lung and organ inflammation treatments
People of CalciMedica
Unlock access to complete
Unlock access to complete
Funding Insights of CalciMedica
CalciMedica has successfully raised a total of $76.66M across 16 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $32.5 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CalciMedica
CalciMedica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, HHS and Avenue Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investments in distressed debt and securities are managed globally.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for CalciMedica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CalciMedica
Investment portfolio details for CalciMedica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CalciMedica
Detailed financials for CalciMedica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Calcimedica Comparisons
Peer comparison for CalciMedica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CalciMedica
CalciMedica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
Detailed competitors of CalciMedica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calcimedica
Complete news archive for CalciMedica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CalciMedica
CalciMedica was founded in 2006 and raised its 1st funding round 1 year after it was founded.
CalciMedica is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
CalciMedica is a funded company, having raised a total of $76.66M across 16 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CalciMedica is 14.
CalciMedica was established in 2006 in San Diego, United States, within the biotechnology sector. A portfolio of selective CRAC channel inhibitor drugs is being advanced by the company to address acute inflammatory conditions. Development efforts are directed toward enhancing patient outcomes in these indications, with operations centered on pharmaceutical innovation for inflammatory diseases.
CalciMedica's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
CalciMedica offers Auxora and CRAC Channel Inhibitors.
Yes, CalciMedica is publicly traded on NASDAQ under the ticker symbol CALC.
CalciMedica has 8 investors. Key investors include Biogen, HHS, Avenue Capital Group, Valence Life Sciences, and Mesa Verde Venture Partners.
The ticker symbol of CalciMedica is CALC on NASDAQ.